Posted on May 29, 2026
During PEGS Boston Summit 2026, OPM primarily attended sessions related to difficult-to-express proteins, protein expression optimization, and accelerated protein production workflows. Across these sessions, several important scientific and industry trends emerged that are highly relevant to the current direction of biologics development and transient transfection technologies.
A major overarching theme throughout the conference was the strong shared focus across both academia and industry on accelerating biologics development timelines while improving expression yields, workflow simplicity, scalability, and compatibility with increasingly complex therapeutic modalities.
One of the most noticeable trends observed during the conference was the increasing focus across both academic and industrial groups on CHO-based transient transfection systems as alternatives to traditional HEK293 workflows.
Several presentations emphasized:
Historically, HEK293 systems have dominated transient expression applications because of their high transfectability and rapid protein production capabilities. However, the conference highlighted significant ongoing efforts to improve CHO transient systems, likely driven by advantages associated with CHO cells in manufacturability, product quality, and smoother transition into stable cell line development workflows.
Overall, the field appears to be moving toward positioning CHO transient expression as both a discovery-and development-compatible platform rather than solely a protein screening tool.
Another major trend observed across the conference was the strong emphasis on simplifying and accelerating protein production workflows.
A recurring focus was placed on:
Rather than optimizing isolated process components, many groups are now developing highly streamlined expression ecosystems designed to reduce the total timeline from construct design to protein generation.
This reflects the broader push across both academia and industry to accelerate biologics development while maintaining reproducibility and scalability. Workflow simplicity is also becoming an increasingly important competitive advantage for transient expression platforms.
Another clear trend throughout the conference was the growing focus on difficult-to-express proteins and increasingly complex therapeutic modalities.
Examples discussed across multiple sessions included:
Many presentations highlighted that traditional optimization strategies are often insufficient for these next-generation biologics. Instead, the field is increasingly adopting more integrated approaches involving:
The conference reinforced the idea that future improvements in protein production will likely require simultaneous optimization of cellular physiology, vector design, and production workflows rather than focusing solely on media or transfection reagent improvements. Nevertheless, robust cell culture media and high-performance transfection reagents remain core enabling technologies that must complement novel approaches to synergistically achieve efficient, scalable, and reproducible transient expression workflows.
One of the strongest emerging trends at the conference was the increasing integration of artificial intelligence (AI), machine learning (ML), and synthetic biology into biologics development workflows.
Applications discussed included:
Both academic and industrial groups are increasingly adopting computationally assisted biologics development strategies where large datasets and predictive models are used to improve:
Importantly, several discussions emphasized that highly reproducible expression systems and rapid experimental validation platforms remain essential for generating the datasets needed to support machine learning-driven optimization.
Overall, the conference highlighted a growing convergence between synthetic biology, automation, and protein expression technologies.
Although mammalian transient expression systems remained a primary focus, there was also increasing attention given to alternative protein production technologies.
These included:
These technologies were mainly presented as complementary tools for:
The growing diversity of expression technologies suggests that the biologics field is moving toward more flexible and application-specific production strategies depending on therapeutic modality and development stage.
Another important trend observed across the conference was the effort to reduce the gap between discovery-stage protein expression and downstream manufacturing development.
Several presentations emphasized:
The field appears to be increasingly focused on creating unified development pipelines that allow earlier process understanding and smoother progression from discovery to manufacturing.
This trend may further increase demand for transient expression systems that more closely mimic stable production environments and manufacturing-relevant conditions.
Overall, PEGS Boston Summit 2026 highlighted several important directions currently shaping the biologics and protein expression field:
Collectively, these trends reflect the broader movement toward faster, more scalable, data-driven, and manufacturing-compatible biologics development platforms.
Many of the trends highlighted during PEGS align closely with the direction of OPM’s transient expression platform portfolio. OPM is well positioned to support these needs through both its HEK293 transient transfection platform (OPM-293 Transient Expression System) and its upcoming CHO transient transfection platform.
In particular, the increasing interest in CHO-based transient expression observed throughout the conference underscores the demand for scalable, manufacturing-compatible protein production solutions — and the potential of OPM's transient platforms to support scientists seeking smoother transition pathways from discovery to production.
To learn more about OPM’s products or request free samples, please contact us.